Antibodies to citrullinated peptides in rheumathoid arthritis;Anticuerpos anticitrulina en la artritis reumatoide

Medicina Clinica

Volumn 128, Issue 17, 2007, Pages 668-673

  Balsa, Alejandro ^a   Pascual Salcedo, Dora ^a   Martín, Javier ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

Antibodies to citrullinated peptid; Autoantibodies; HLA DRB1; Rheumathoid artritis; Rheumathoid factor

Indexed keywords

AUTOANTIBODY; CITRULLINE; PEPTIDE ANTIBODY; RHEUMATOID FACTOR;

ANTIBODY BLOOD LEVEL; AUTOIMMUNE DISEASE; AUTOIMMUNITY; DIAGNOSTIC TEST; ENVIRONMENTAL FACTOR; GENETIC ASSOCIATION; HUMAN; IMMUNE RESPONSE; PATHOGENESIS; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; SYMPTOMATOLOGY;

EID: 34347236866     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13102061     Document Type: Review

References (59)

1. Carmona L, Villaverde V, Hernández-García C, Ballina J, Gabriel R, Laffón A, et al. The prevalence of rheumatoid arthritis in the general population of Spain. Rheumatology (Oxford). 2002;41:88-95.
2. Smolen JS, Aletaha D, Machold KP. Therapeutic strategies in early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2005;19:163-77.
3. Arnett FC, Edworthy SM, Bloch DA, McShane DA, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.
4. Westwood OM, Nelson PN, Hay FC. Rheumatoid factors: what's new? Rheumatology (Oxford). 2006;45:379-85.
5. Van Boekel MA, Vossenaar ER, Van den Hoogen FH, Van Venrooij WJ. Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res. 2002;4:87-93.
6. Nienhuis RLF, Mandema EA. A new serum factor in patients with rheumatoid arthritis. The antiperinuclear factor. Ann Rheum Dis. 1964;23: 302-5.
7. Young BJ, Mallya RK, Leslie RD, Clark CJ, Hamblin TJ. Antikeratin antibodies in rheumatoid arthritis. BMJ. 1979;2:97-9.
8. Sebbag M, Simon M, Vincent C, Masson-Besiere C, Girbal E, Durieux JJ et al. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1995;95:2672-9.
9. Muñoz FS, Alvarez DR, Cuesta M, Balsa A, Fontan G, Gijón J. Antiperinuclear factor: a useful test for the diagnosis of rheumatoid arthritis. Rheumatol Int. 1995;15:145-9.
10. Muñoz FS, Alvarez DR, Gonzalez-Tarrio JM, Balsa A, Richi P, Fontan G. et al. Antiperinuclear factor as a prognostic marker in rheumatoid arthritis. J Rheumatol. 1999;26:2572-7.
11. Vincent C, De Keyser F, Masson-Besiere C, Sebbag M, Veys EM, Serre G. Anti-perinuclear factor compared with the so called "antikeratin" antibodies and antibodies to human epidermis filaggrin, in the diagnosis of arthritides. Ann Rheum Dis. 1999;58:42-8.
12. Schellekens GA, De Jong BA, Van-den Hoogen FH, Van-de PLB, Van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101:273-81.
13. Girbal-Neuhauser E, Durieux JJ, Arnaud M, Dalbon P, Sebbag M, Vincent, et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol. 1999;162:585-94.
14. Nogueira L, Sebbag M, Vincent C, Arnaud M, Fournie B, Cantagrel A, et al. Performance of two ELISAs for antifilaggrin autoantibodies, using either affinity purified or deiminated recombinant human filaggrin, in the diagnosis of rheumatoid arthritis. Ann Rheum Dis. 2001;60:882-7.
15. Vincent C, Nogueira L, Sebbag M, Chapuy-Regaud S, Arnaud M, Letourneur O, et al. Detection of antibodies to deiminated recombinant rat filaggrin by enzyme-linked immunosorbent assay: a highly effective test for the diagnosis of rheumatoid arthritis. Arthritis Rheum. 2002;46: 2051-8.
16. Schellekens GA, Visser H, De Jong BA, Van-den Hoogen FH, Hazes JM, Breedveld F et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000;43:155-63.
17. Zendman AJ, Van Venrooij WJ, Pruijn GJ. Use and significance of anti-CCP autoantibodies in rheumatoid arthritis. Rheumatology (Oxford). 2006; 45:20-5.
18. Vossenaar ER, Van Venrooij WJ. Anti-CCP antibodies, a highly specific marker for (early) rheumatoid arthritis. Clin Appl Immunol Rev. 2004; 4:239-62.
19. Van Venrooij WJ, Vossenaar ER, Zendman AJ. Anti-CCP antibodies: the new rheumatoid factor in the serology of rheumatoid arthritis. Autoimmun Rev. 2004;3 Suppl 1:S17-S19.
20. Avouac J, Gossec L, Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis. 2006;65:845-51.
21. De Rycke L, Peene I, Hoffman IE, Kruithof E, Union A, Meheus L, et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis. 2004;63:1587-93.
22. Salvador G, Gomez A, Viñas O, Ercilla G, Cañete JD, Muñoz-Gómez J et al. Prevalence and clinical significance of anti-cyclic citrullinated peptide and antikeratin antibodies in palindromic rheumatism. An abortive form of rheumatoid arthritis? Rheumatology (Oxford). 2003;42:972-5.
23. Riedemann JP, Munoz S, Kavanaugh A. The use of second generation anti-CCP antibody (anti-CCP2) testing in rheumatoid arthritis - a systematic review. Clin Exp Rheumatol. 2005;23 5 Suppl 39:S69-S76.
24. Vannini A, Cheung K, Fusconi M, Stammen-Vogelzangs J, Drenth JP, Dall'aglio AC, et al. Anti-CCP2 positivity in non-RA disease samples: citrulline-dependent or not? Ann Rheum Dis. 2006. (En prensa).
25. Nielen MM, Van SD, Reesink HW, Van de Stadt RJ, Van der Horst-Bruinsma IE, De Koning MH, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004;50:380-6.
26. Rantapaa-Dahlqvist S, De Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003;48:2741-9.
27. Berglin E, Padyukov L, Sundin U, Hallmans G, Stenlund H, Van Venrooij WJ, et al. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther. 2004;6:R303-R308.
28. Kroot EJ, De Jong BA, Van Leeuwen MA, Swinkels HL, Van-den Hoogen FH, Van't Hof MA, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2000;43:1831-5.
29. Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis. 2004;63:1090-5.
30. Nielen MM, Van der Horst AR, Van SD, Van der Horst-Bruinsma IE, Van de Stadt RJ, Aarden L, et al. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis. 2005;64:1199-204.
31. Van Gaalen FA, Visser H, Huizinga TW. A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis. Ann Rheum Dis. 2005;64:1510-2.
32. Van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther. 2005;7:R949-R958.
33. Jansen AL, Van-der H-BIE, Van Schaardenburg D, Van de Stadt RJ, De Koning MH, Dijkmans BA. Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol. 2002;29:2074-6.
34. Visser H, Le Cessie S, Vos K, Breedveld FC, Hazes JM. How to diagnose rheumatoid arthritis early. A prediction model for persistent (erosive) arthritis. Arthritis Rheum. 2002;46:357-65.
35. Vossenaar ER, Zendman AJ, Van Venrooij WJ, Pruijn GJ. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays. 2003;25:1106-18.
36. Asaga H, Yamada M, Senshu T. Selective deimination of vimentin in calcium ionophore-induced apoptosis of mouse peritoneal macrophages. Biochem Biophys Res Commun. 1998;243:641-6.
37. Masson-Bessiere C, Sebbag M, Girbal-Neuhauser E, Nogueira L, Vincent C, Senshu T, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha-and beta-chains of fibrin. J Immunol. 2001;166:4177-84.
38. Vossenaar ER, Despres N, Lapointe E, Van der Horst A, Lora M, Senshu T, et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther. 2004;6:R142-R150.
39. Vossenaar ER, Nijenhuis S, Helsen MM, Van der Horst A, Senshu T, Van den Berg WB, et al. Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis Rheum. 2003;48:2489-500.
40. Vossenaar ER, Smeets TJ, Kraan MC, Raats JM, Van Venrooij WJ, Tak PP. The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum. 2004;50:3485-94.
41. De Rycke L, Nicholas AP, Cantaert T, Kruithof E, Echols JD, Vandekerckhove B, et al. Synovial intracellular citrullinated proteins colocalizing with peptidyl arginine deiminase as pathophysiologically relevant antigenic determinants of rheumatoid arthritis-specific humoral autoimmunity. Arthritis Rheum. 2005;52:2323-30.
42. Van Gaalen F, Ioan-Facsinay A, Huizinga TW, Toes RE. The devil in the details: the emerging role of anticitrulline autoimmunity in rheumatoid arthritis. J Immunol. 2005;175:5575-80.
43. Kuhn KA, Kulik L, Tomooka B, Braschler KJ, Arend WP, Robinson WH, et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest. 2006;116:961-73.
44. Gregersen PK, Silver J, Winchester R. The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987;30:1205-13.
45. Zanelli E, Breedveld FC, De Vries RR. HLA class II association with rheumatoid arthritis: facts and interpretations. Hum Immunol. 2000;1:1254-61.
46. Hill J, Cairns E, Bell DA. The joy of citrulline: new insights into the diagnosis, pathogenesis, and treatment of rheumatoid arthritis. J Rheumatol. 2004;31:1471-3.
47. Huizinga TW, Amos CI, Van der Helm-van Mil AH, Chen W, Van Gaalen FA, Jawaheer D, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum. 2005;52:3433-8.
48. Irigoyen P, Lee AT, Wener MH, Li W, Kern M, Batliwalla F, et al. Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles. Arthritis Rheum. 2005;52:3813-8.
49. Orozco G, Pascual-Salcedo D , López-Nevot MA, Cobo T, Martín-Mola E, Balsa A, et al. Autoantibodies, HLA and PTPN22: Susceptibility markers for rheumatoid arthritis. Manuscrito enviado. Arthitis Res Ther.
50. Masson-Bessiere C, Sebbag M, Durieux JJ, Nogueira L, Vincent C, Girbal-Neuhauser E et al. In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin Exp Immunol. 2000;119:544-52.
51. Reparon-Schuijt CC, Van Esch WJ, Van KC, Schellekens GA, De Jong BA, Van Venrooij WJ, et al. Secretion of anti-citrulline-containing peptide antibody by B lymphocytes in rheumatoid arthritis. Arthritis Rheum. 2001; 44:41-7.
52. Plenge RM, Padyukov L, Remmers EF, Purcell S, Lee AT, Karlson EW, et al. Replication of putative candidate-gene associations with rheumatoid arthritis in > 4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet. 2005;77:1044-60.
53. Martinez A, Valdivia A, Pascual-Salcedo D, Lamas JR, Fernandez-Arquero M, Balsa A, et al. PADI4 polymorphisms are not associated with rheumatoid arthritis in the Spanish population. Rheumatology (Oxford). 2005;44:1263-6.
54. Caponi L, Petit-Teixeira E, Sebbag M, Bongiorni F, Moscato S, Pratesi F, et al. A family based study shows no association between rheumatoid arthritis and the PADI4 gene in a white French population. Ann Rheum Dis. 2005;64:587-93.
55. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54:38-46.
56. Klareskog L, Padyukov L, Ronnelid J, Alfredsson L. Genes, environment and immunity in the development of rheumatoid arthritis. Curr Opin Immunol. 2006;18:650-5.
57. Gómez RJ, Maceiras F. La genética de la artritis reumatoide. Med Clin (Barc). 2000;114:16-8.
58. Orozco G, Sanchez E, Gonzalez-Gay MA, Lopez-Nevot MA, Torres B, Caliz R, et al. Association of a functional single-nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum. 2005;52: 219-24.
59. Johansson M, Arlestig L, Hallmans G, Rantapaa-Dahlqvist S. PTPN22 polymorphism and anti-cyclic citrullinated peptide antibodies in combination strongly predicts future onset of rheumatoid arthritis and has a specificity of 100% for the disease. Arthritis Res Ther. 2005;8:R19.